Projects per year
Personal profile
Biography
Professor William Sievert is a clinician-scientist with dual appointments at Monash University and Monash Health as the Director of the Gastrointestinal and Liver Unit. Professor Sievert has a long-term interest in liver disease and directs an active clinical research unit comprising physician-scientists, clinical research nurses and research students.
The Clinical Research Unit has been continuously active over ten years and regularly contributes to international trials of new antiviral agents for hepatitis B and C in addition to developing and leading national investigator-initiated studies. He also directs a basic research laboratory investigating mechanisms of inflammatory liver injury and hepatic fibrogenesis, with a translational focus on identification and development of potential hepatic antifibrotic agents.
Professor Sievert is also active in medical education including the development of new undergraduate and graduate medical curricula at Monash University.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Network
-
Locally administered extracellular vesicles for perianal fistulising Crohn's disease
Moore, G., Keung, C. Y. Y., Lim, R., Sievert, W. & Nguyen, T. C.
1/06/21 → 28/02/25
Project: Research
-
Engineering a solution to non-alcoholic steatohepatitis through tuning substrate stiffness
Lim, R., Sievert, W., Wallace, E., Frith, J., Greening, D. W. & Kusuma, G.
1/06/20 → 31/05/22
Project: Research
-
A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma
24/01/20 → 23/01/25
Project: Research
-
Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells
Goonetilleke, M., Kuk, N., Correia, J., Hodge, A., Moore, G., Gantier, M. P., Yeoh, G., Sievert, W. & Lim, R., Dec 2021, In: Stem Cell Research and Therapy. 12, 1, 13 p., 429.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Amnion Epithelial Cells — a Therapeutic Source
Schwab, R. H. M., Goonetilleke, M., Zhu, D., Kusuma, G. D., Wallace, E. M., Sievert, W. & Lim, R., Mar 2021, In: Current Stem Cell Reports. 7, 1, p. 13–29 17 p.Research output: Contribution to journal › Review Article › Research › peer-review
-
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics
Papaluca, T., Roberts, S. K., Strasser, S. I., Stuart, K. A., Farrell, G., Macquillan, G., Dore, G. J., Wade, A. J., George, J., Hazeldine, S., O'Beirne, J., Wigg, A., Fisher, L., McGarity, B., Sawhney, R., Sinclair, M., Thomas, J., Valiozis, I., Weltman, M., Wilson, M. & 17 others, , 1 Nov 2021, In: Clinical Infectious Diseases. 73, 9, p. E3288-E3295 8 p.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus) -
Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools
Braude, M. R., Con, D., Lubel, J., Bidwai, A., Nguyen, H. T., Sharmamiglani, S., Clarke, D., Dev, A. & Sievert, W., Jun 2021, In: Hepatology International. 15, 3, p. 812-820 9 p.Research output: Contribution to journal › Article › Research › peer-review
-
The case for simplifying and using absolute targets for viral hepatitis elimination goals
Polaris Observatory Collaborators, Jan 2021, In: Journal of Viral Hepatitis. 28, 1, p. 12-19 8 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access10 Citations (Scopus)